Modified antibody in fetal alloimmunization Comment uri icon

Overview

MeSH Major

  • Antibodies
  • Recombinant Proteins
  • Thrombocytopenia, Neonatal Alloimmune

abstract

  • In this issue of Blood, Ghevaert et al propose to develop a therapeutic antibody for fetal and neonatal alloimmune thrombocytopenia (FNAIT) that would block the actual antibody in sensitized mothers from binding and therefore prevent, or at least ameliorate, fetal and neonatal thrombocytopenia in fetuses who would otherwise be affected.1 The goal of the group is to engineer an antibody reagent that would on the one hand not engage conventional activating Fc receptors and on the other hand interact normally with FcRn, allowing transplacental passage.

publication date

  • July 18, 2013

Research

keywords

  • Comment

Identity

Digital Object Identifier (DOI)

  • 10.1182/blood-2013-05-502625

PubMed ID

  • 23869072

Additional Document Info

start page

  • 303

end page

  • 4

volume

  • 122

number

  • 3